Clinical Trials

Inclusion Criteria:

- Patients with either an imaging diagnosis of HCC by CT or MRI (Liver Imaging Reporting
and Data System [LI-RADS] 5) confirmed by a board-certified abdominal radiologist, or
with biopsy-proven HCC

- No prior treatment for HCC

- Patients who may undergo hepatic surgical resection or liver transplant

- Male or female with age greater than 18 years, with the capacity and willingness to
provide written informed consent

Exclusion Criteria:

- Patients requiring emergent surgery for a ruptured/bleeding HCC

- Bilirubin > 3.0 mg/dL, which is a contraindication for Gadoxetate, the MRI contrast
agent (relevant to PET/MRI)

- Patients with glomerular filtration rate (GFR) < 30 ml/min/1.73m^2, on dialysis, or
with acute kidney injury

- Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of
the PET scan

- Patients with higher than the weight/size limitations of PET/MRI or PET/CT scanner

- Subjects with history of allergic response to Eovist or Gadavist

- Subjects with known history of claustrophobia

- Subjects with GFR < 30 ml/min/1.73m^2, on dialysis, or with acute kidney injury

- Subjects with a history of severe hypersensitivity to Eovist or Gadavist

- Patients with contraindication to MRI (relevant to PET/MRI):

- Patients who have a heart pacemaker

- Patients who have a metallic foreign body (metal sliver) in their eye, or who
have an aneurysm clip in their brain

- Patients who have implanted devices with magnets

- Patients who have other implanted electronic devices

- Patients who have deep brain stimulator

- Patients who have vagal nerve stimulator

- Patients with cochlear (ear) or auditory implants

Eligibility last updated 6/30/22. Questions regarding updates should be directed to the study team contact.